These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34999929)

  • 81. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
    Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
    Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies.
    Shin DY; Lee JH; Park S; Lee JO; Moon JH; Ahn JS; Choi Y; Song IC; Shin HJ; Lee WS; Lee HS; Yoon SS
    Bone Marrow Transplant; 2018 Feb; 53(2):207-212. PubMed ID: 29084202
    [TBL] [Abstract][Full Text] [Related]  

  • 84. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions.
    Galambrun C; Pondarré C; Bertrand Y; Loundou A; Bordigoni P; Frange P; Lutz P; Mialou V; Rubie H; Socié G; Schneider P; Bernaudin F; Paillard C; Michel G; Badens C; Thuret I; ;
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):62-8. PubMed ID: 22892550
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Improved Outcome Following Busulfan-Based Conditioning in Children with Functional Neutrophil Disorders Undergoing Hematopoietic Stem Cell Transplant from HLA-Matched Donors.
    Jacoby E; Adam E; Hutt D; Somech R; Malkiel S; Toren A; Bielorai B
    J Clin Immunol; 2023 Oct; 43(7):1603-1610. PubMed ID: 37310531
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
    Yamamoto W; Andou T; Itabashi M; Koyama S; Ishii Y; Numata A; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S
    Intern Med; 2016; 55(13):1721-7. PubMed ID: 27374671
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.
    Burroughs LM; Shimamura A; Talano JA; Domm JA; Baker KK; Delaney C; Frangoul H; Margolis DA; Baker KS; Nemecek ER; Geddis AE; Sandmaier BM; Deeg HJ; Storb R; Woolfrey AE
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1669-1677. PubMed ID: 28602958
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial.
    Sykora KW; Beier R; Schulz A; Cesaro S; Greil J; Gozdzik J; Sedlacek P; Bader P; Schulte J; Zecca M; Locatelli F; Gruhn B; Reinhardt D; Styczynski J; Piras S; Fagioli F; Bonanomi S; Caniglia M; Li X; Baumgart J; Kehne J; Mielcarek-Siedziuk M; Kalwak K
    Bone Marrow Transplant; 2024 Jan; 59(1):107-116. PubMed ID: 37925531
    [TBL] [Abstract][Full Text] [Related]  

  • 90. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial.
    Mehta RS; Bassett R; Chen J; Valdez BC; Kawedia J; Alousi AM; Anderlini P; Al-Atrash G; Bashir Q; Ciurea SO; Hosing CM; Im JS; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Qazilbash MH; Ramdial J; Saini N; Srour SA; Rezvani K; Shpall EJ; Andersson BS; Champlin RE; Popat UR
    Transplant Cell Ther; 2021 Nov; 27(11):913.e1-913.e12. PubMed ID: 34329753
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies.
    Kalwak K; Mielcarek M; Patrick K; Styczynski J; Bader P; Corbacioglu S; Burkhardt B; Sykora KW; Drabko K; Gozdzik J; Fagioli F; Greil J; Gruhn B; Beier R; Locatelli F; Müller I; Schlegel PG; Sedlacek P; Stachel KD; Hemmelmann C; Möller AK; Baumgart J; Vora A
    Bone Marrow Transplant; 2020 Oct; 55(10):1996-2007. PubMed ID: 32203268
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
    Sun L; Wang N; Chen Y; Tang L; Xing C; Lu N; Shi Y; Ma Y; Lin F; Yu K; Feng J
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
    Lam W; Storek J; Li H; Geddes M; Daly A
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
    Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
    Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Nagler A
    Leuk Lymphoma; 2007 Dec; 48(12):2352-9. PubMed ID: 18067010
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).
    Patel P; Sweiss K; Nimmagadda S; Gao W; Rondelli D
    Bone Marrow Transplant; 2011 Oct; 46(10):1326-30. PubMed ID: 21132027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.